Researchers from The University of Texas Medical Branch at Galveston have developed the first vaccine for chikungunya fever made from an insect-specific virus that doesn’t have any effect on people, making the vaccine safe and effective. The newly developed vaccine quickly produces a strong immune defense and completely protects mice and nonhuman primates from disease when exposed to the chikungunya virus.
The findings are detailed in Nature Medicine.
“This vaccine offers efficient, safe and affordable protection against chikungunya and builds the foundation for using viruses that only infect insects to develop vaccines against other insect-borne diseases,” said UTMB professor Scott Weaver, senior author of this paper.
Chikungunya is a mosquito-borne virus that causes a disease characterized by fever and severe joint pain, often in hands and feet, and may include headache, muscle pain, joint swelling, or rash. Some patients will feel better within a week but many develop longer-term joint pain that can last up to years. Death is rare but can occur.
Traditionally, vaccine development involves tradeoffs between how quickly the vaccine works and safety. Live-attenuated vaccines that are made from weakened versions of a live pathogen typically offer rapid and durable immunity but reduced safety. On the other hand, the inability of inactivated vaccines to replicate enhances safety at the expense of effectiveness, often requiring several doses and boosters to work properly. There may be a risk of disease with both of these vaccine types, either from incomplete inactivation of the virus or from incomplete or unstable weakening of the live virus that is only recognized when rare vulnerable individuals develop disease.
To overcome these tradeoffs, the researchers used the Eilat virus as a vaccine platform since it only infects insects and has no impact on people. The UTMB researchers used an Eilat virus clone to design a hybrid virus-based vaccine containing chikungunya structural proteins.
The Eilat/Chikungunya vaccine was found to be structurally identical to natural chikungunya virus. The difference is that although the hybrid virus replicates very well in mosquito cells, it cannot replicate in mammals.
Within four days of a single dose, the Eilat/Chikungunya candidate vaccine induced neutralizing antibodies that lasted for more than 290 days. The antibodies provided complete protection against chikungunya in two different mouse models. In nonhuman primates, Eilat/Chikungunya elicited rapid and robust immunity – there was neither evidence of the virus in the blood nor signs of illness such as fever after chikungunya virus infection.
Learn more: UTMB researchers develop first chikungunya vaccine from virus that does not affect people
[osd_subscribe categories=’chikungunya’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “CHIKUNGUNYA”‘]
Receive an email update when we add a new CHIKUNGUNYA article.
The Latest on: Chikungunya vaccine
[google_news title=”” keyword=”Chikungunya vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Chikungunya vaccine
- Vice President Dhankhar visits Bharat Biotech's facilities, urges greater industry-academia collaboration in researchon April 26, 2024 at 11:04 am
Vice President Jagdeep Dhankhar on Friday visited Bharat Biotech facilities at Genome Valley, Hyderabad, which focused on innovation, research and development ...
- Vice President Jagdeep Dhankhar Concludes Visit to Bharat Biotech's Hyderabad Facilityon April 26, 2024 at 8:04 am
Vice President Dhankar visited Bharat Biotech's research, development, and manufacturing facilities in Hyderabad, Telangana. He praised the company's role in India's immunization programs and its ...
- Hyderabad: VP Jagdeep Dhankhar tours Bharat Biotech manufacturing facilityon April 26, 2024 at 7:07 am
Dhankhar interacted with the scientists and team leaders and applauded the collective determination to develop novel vaccines and make India self-reliant ...
- Vice President Jagdeep Dhankhar visits Bharat Biotech in Hyderabad's Genome Valleyon April 25, 2024 at 5:00 pm
and the company’s initiatives to develop new molecules and vaccine candidates to fight neglected diseases that affect the developing world, specifically focused on malaria, cholera, tuberculosis, and ...
- Why malaria is on the rise – and how to protect yourself on holidayon April 25, 2024 at 10:00 am
Returning from a tropical holiday should come with a suntan and sense of relaxation – not a tropical disease. However, the number of British travellers catching malaria abroad is rising, and ...
- Vaccines are a glimmer of hope against malaria, but the battle has only just begunon April 25, 2024 at 6:10 am
By the time you reach the end of this article, three children will have died from malaria – a disease that casts a dark shadow over nearly half of the world’s population, claiming victims ...
- Spike in arboviral diseases shows need for vaccine development: experton April 23, 2024 at 6:58 am
The rising incidence and spread of arboviral diseases to new places show the need for the development of new vaccines, project leader for the mRNA and viral ...
- Dengue cases top 5.2 million in the Americas as outbreak passes yearly record, PAHO sayson April 19, 2024 at 3:40 pm
Dengue cases are surging in the Americas, with cases reported topping 5.2 million as of this week, surpassing a yearly record set in 2023, according to the Pan American Health Organization (PAHO).
- After coming up short in COVID, Valneva focuses on chikungunya vaccine launchon April 18, 2024 at 9:02 am
Thomas Lingelbach, CEO of French vaccine specialist Valneva, said that the company is focused on launching its newly approved shot for the chikungunya virus and on developing a second-generation ...
via Bing News